The mechanisms of B-cell acute lymphoblastic leukemia relapsing following chimeric antigen receptor-T cell therapy; the plausible future strategies

Mol Biol Rep. 2024 Nov 8;51(1):1135. doi: 10.1007/s11033-024-10061-2.

Abstract

Research has demonstrated the high mortality and morbidity associated with B-Acute lymphoblastic lymphoma (B-ALL). Researchers have developed several therapeutic approaches to combat the disorder. Recently, researchers developed chimeric antigen receptors (CARs)-T cells, which recognize antigens independently of major histocompatibility complexes (MHCs) and activate at a higher level with additional persistence. However, relapsing B-ALL has been reported in several cases. This review article was aimed to collecting recent information regarding the mechanisms used by B-ALL-related lymphocytes to escape from CAR-T cells and the plausible resolution projects.

Keywords: B-Acute lymphoblastic lymphoma; Chimeric antigen receptor; Relapsing.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunotherapy, Adoptive* / methods
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / immunology
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / therapy
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / immunology
  • Receptors, Antigen, T-Cell / metabolism
  • Receptors, Chimeric Antigen* / immunology
  • Recurrence
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism

Substances

  • Receptors, Chimeric Antigen
  • Receptors, Antigen, T-Cell